Skip to content
The Policy VaultThe Policy Vault

Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) — United Healthcare

Chronic hepatitis C genotype 1a or 3 infection in treatment-experienced patients with a sofosbuvir-containing regimen without an NS5A inhibitor who are without cirrhosis or have compensated cirrhosis

Initial criteria

  • Diagnosis of chronic hepatitis C genotype 1a or 3 infection
  • AND Patient has prior treatment experience with a regimen containing Sovaldi (sofosbuvir) without an NS5A inhibitor
  • AND One of the following: (a) Patient is without cirrhosis OR (b) Patient has compensated cirrhosis (Child-Pugh A)
  • AND Patient is not receiving Vosevi in combination with another HCV direct acting antiviral agent [e.g., Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Mavyret (glecaprevir/pibrentasvir), Sovaldi (sofosbuvir), Zepatier (elbasvir/grazoprevir)]

Approval duration

12 weeks